Our examination revealed that circulating soluble suppression of tumorigenicity 2 (sST2), Cardiotrophin-1 (CT-1), and galectin-3 levels correlate closely with DCM progression stages. The gene discussed is LGALS3; the disease is familial dilated cardiomyopathy.